17 results on '"Mosenzon, Ofri"'
Search Results
2. RELATIONSHIP BETWEEN CYSTATIN C, CREATININE-BASED EGFR, CARDIOVASCULAR EVENTS AND KIDNEY OUTCOMES IN DECLARETIMI 58
3. RISK OF KIDNEY DISEASE PROGRESSION AND EFFICACY OF SGLT2 INHIBITION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
4. FIBROBLAST GROWTH FACTOR-23, CARDIORENAL OUTCOMES, AND EFFICACY OF DAPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: AN ANALYSIS FROM DECLARE-TIMI 58
5. Causes and Risk Factors for Death in Diabetes: A Competing-Risk Analysis From the SAVOR-TIMI 53 Trial
6. MEDIATION ANALYSIS FOR DAPAGLIFLOZIN AND THE REDUCTION IN HOSPITALIZATION FOR HEART FAILURE IN DECLARE-TIMI 58
7. SEMAGLUTIDE REDUCES HIGH-SENSITIVITY CRP LEVELS ACROSS DIFFERENT TREATMENT FORMULATIONS: EXPLORATORY ANALYSES OF SUSTAIN 3 AND PIONEER 1, 2 AND 5 TRIALS
8. EFFECTS OF DAPAGLIFLOZIN ON CARDIOVASCULAR OUTCOMES ACROSS BODY MASS INDEX CATEGORIES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN THE DECLARE TIMI 58 TRIAL
9. PERFORMANCE OF A NOVEL GENETIC RISK SCORE TO IDENTIFY RISK OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH CARDIOMETABOLIC DISEASE
10. DAPAGLIFLOZIN AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES AND PRIOR MYOCARDIAL INFARCTION: A SUB-ANALYSIS FROM DECLARE TIMI-58 TRIAL
11. NATRIURETIC PEPTIDES VERSUS A CLINICAL HISTORY OF HEART FAILURE FOR RISK PREDICTION IN PATIENTS WITH DIABETES
12. INFLAMMATORY AND CARDIAC BIOMARKERS ARE ASSOCIATED WITH RENAL OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: INSIGHTS FROM SAVOR-TIMI 53
13. BLOOD PRESSURE, SUBCLINICAL MYOCARDIAL INJURY AND CARDIOVASCULAR OUTCOMES AMONG PATIENTS WITH DIABETES AND HIGH CARDIOVASCULAR RISK: OBSERVATIONS FROM THE SAVOR-TIMI 53 TRIAL
14. RISK STRATIFICATION WITH THE TIMI RISK SCORE FOR SECONDARY PREVENTION AMONG PATIENTS WITH DIABETES AND ELEVATED CARDIOVASCULAR RISK
15. CLINICAL FACTORS ASSOCIATED WITH SUDDEN CARDIAC DEATH IN TYPE 2 DIABETES: INSIGHTS FROM THE SAVOR-TIMI 53 TRIAL
16. PATTERNS OF ASPIRIN UTILIZATION AND OUTCOMES AMONG PATIENTS WITH DIABETES MELLITUS: A PROPENSITY SCORE MATCHED ANALYSIS FROM THE SAVOR-TIMI 53 TRIAL
17. BASELINE RENAL FUNCTION AND CARDIOVASCULAR RISK IN PATIENTS TREATED WITH SAXAGLIPTIN: OBSERVATIONS FROM THE SAVOR-TIMI 53 TRIAL
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.